Patents Assigned to CEBIX AB
  • Patent number: 8962553
    Abstract: The present invention relates to PEGylated C-peptide derivatives comprising at least one PEG group attached to the N-terminus, which exhibit improved pharmacokinetic and biological activity in vivo.
    Type: Grant
    Filed: November 19, 2012
    Date of Patent: February 24, 2015
    Assignee: Cebix AB
    Inventors: John Wahren, Sheri Barrack, James Callaway, Michelle Mazzoni, Howard Foyt, Mark Daniels
  • Publication number: 20140378394
    Abstract: The present invention relates to the development of improved methods for treating erectile dysfunction associated with diabetes. Significantly, such dosing regimens can be combined with established methods for treating sexual dysfunction, including phosphodiesterase-5 (PDE5) inhibitors such as those sold under the trademark VIAGRA® to provide for significantly improved efficacy compared to the PDE5 inhibitor alone.
    Type: Application
    Filed: June 2, 2014
    Publication date: December 25, 2014
    Applicant: CEBIX AB
    Inventor: John WAHREN
  • Patent number: 8691755
    Abstract: The present invention relates to modified forms of C-peptide, and methods for their use. In one aspect, the modified forms of C-peptide comprise PEGylated C-peptide derivatives comprising at least one PEG group attached to the N-terminus, which exhibit superior pharmacokinetic and biological activity in vivo.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: April 8, 2014
    Assignee: Cebix AB
    Inventors: Sheri Barrack, James Callaway, Michelle Mazzoni
  • Publication number: 20130345124
    Abstract: Improved methods and kits for treating the long-term complications of diabetes that reduce the risk of the patient developing hypoglycemia during C-peptide therapy. The use of such methods and kits can also maintain good glycemic control and avoid excessive weight gain that may otherwise be associated with excessive insulin administration or caloric intake during C-peptide therapy.
    Type: Application
    Filed: March 1, 2013
    Publication date: December 26, 2013
    Applicant: Cebix AB
    Inventors: John Wahren, Karin Ekberg, James Callaway
  • Publication number: 20130130973
    Abstract: The present invention relates to PEGylated C-peptide derivatives comprising at least one PEG group attached to the N-terminus, which exhibit improved pharmacokinetic and biological activity in vivo.
    Type: Application
    Filed: November 19, 2012
    Publication date: May 23, 2013
    Applicant: CEBIX AB
    Inventor: CEBIX AB
  • Publication number: 20110098220
    Abstract: The present invention provides improved methods and kits for treating the long-term complication of diabetes that reduce the risk of the patient developing hypoglycemia during C-peptide therapy. The use of such methods and kits, can also maintain good glycemic control, and avoid excessive weight gain that may otherwise be associated with excessive insulin administration or caloric intake during C-peptide therapy.
    Type: Application
    Filed: March 4, 2010
    Publication date: April 28, 2011
    Applicant: CEBIX AB
    Inventors: John Wahren, Karin Ekberg, James Callaway